For Patients:
Find out more about clinical trials, why they are done, how you can join a trial and what you can expect if you decide to take part in a trial.
Learn more about clinical trials

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Description
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

View Eligibility & Trial Details >
https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx
Last reviewed:
Last modified: 8/16/2023 10:09 AM
Back to Top